Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m
Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company by both AbbVie Ventures and Roche Venture Fund
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets
Enthera Pharmaceuticals ( Enthera ), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the final closing of its Series A financing, with a total financing of €35m.